 |
Information on Simvastatin/Amiodarone
FDA ALERT [08/08/2008]: The FDA is notifying the public of the risk of a rare condition of muscle injury called rhabdomyolysis, which can lead to kidney failure or death, when simvastatin is used with amiodarone. This risk is dose-related and increases when a dose of simvastatin greater than 20 mg per day is given with amiodarone. A revision of the simvastatin labeling in 2002 described an increased risk of rhabdomyolysis when amiodarone is taken with simvastatin doses greater than 20 mg daily. However, the FDA continues to receive reports of rhabdomyolysis in patients treated concurrently with amiodarone and simvastatin, particularly with simvastatin doses greater than 20 mg daily. Prescribers should be aware of the increased risk of rhabdomyolysis when simvastatin is prescribed with amiodarone, and they should avoid doses of simvastatin greater than 20 mg per day in patients taking amiodarone.
This information reflects FDA's current analysis of data available to FDA concerning this drug. FDA intends to update this when additional information or analyses become available.
- Healthcare Professional Information
Other Information
- Simvastatin, Ezetimibe/Simvastatin, and Amiodaroneis marketed under these names:
Report Adverse Events to MedWatch
 Back
to Top 
Back to Drug Information
 PDF requires the free Adobe Acrobat Reader
Date created: August 8, 2008 |
|
